https://scholars.lib.ntu.edu.tw/handle/123456789/590435
標題: | Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients | 作者: | Li Y.-H. Yeh H.-I. JIANN-SHING JENG Charng M.-J. |
關鍵字: | Dyslipidemia; Guideline; Statin; Taiwan | 公開日期: | 2018 | 卷: | 81 | 期: | 10 | 起(迄)頁: | 853-859 | 來源出版物: | Journal of the Chinese Medical Association | 摘要: | Dyslipidemia is a major contributor in initiation, development and progression of atherosclerotic cardiovascular disease (ASCVD). Most lipid guidelines are from Europe and America and centered on the reduction of atherogenic lipids levels through lifestyle intervention and pharmacotherapy. Recently, the 2017 Taiwan lipid guidelines for high risk patients was published to facilitate the control of dyslipidemia in patients that are highly susceptible to ASCVD, including patients with preexisting ASCVD, diabetes, chronic kidney disease and familial hypercholesterolemia. Most recommendations outlined in the 2017 Taiwan lipid guidelines for high risk patients are in concordance with those of Western guidelines. However, based on evidence from the studies originating from Asia and local expert opinions, there are some recommendations different from the other guidelines. The purpose of the current review is to compare the similarities and differences between the perspectives of the 2017 Taiwan lipid guidelines for high risk patients and other Western guidelines in individuals at high risk of ASCVD. The definitions of high risk groups and treatment goals defined to achieve ASCVD risk reduction are specifically compared. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049337985&doi=10.1016%2fj.jcma.2018.05.003&partnerID=40&md5=8aa78e3d1dc5538463eb6244b9cd7864 https://scholars.lib.ntu.edu.tw/handle/123456789/590435 |
ISSN: | 17264901 | DOI: | 10.1016/j.jcma.2018.05.003 | SDG/關鍵字: | ezetimibe; ezetimibe plus simvastatin; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; hypocholesterolemic agent; lipid; low density lipoprotein cholesterol; proprotein convertase 9; serine proteinase inhibitor; simvastatin; triacylglycerol; lipid; acute coronary syndrome; brain hemorrhage; brain ischemia; cardiovascular risk; cerebrovascular accident; chronic kidney failure; comparative study; coronary artery atherosclerosis; diabetes mellitus; diabetic patient; disease severity; dyslipidemia; familial hypercholesterolemia; high risk patient; human; lifestyle modification; peripheral occlusive artery disease; practice guideline; Review; risk assessment; risk reduction; secondary prevention; Taiwan; western medicine; atherosclerosis; blood; cardiovascular disease; dyslipidemia; practice guideline; Taiwan; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Humans; Hyperlipoproteinemia Type II; Lipids; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Taiwan |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。